These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
454 related articles for article (PubMed ID: 32092618)
21. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications. Croessmann S; Park BH Clin Adv Hematol Oncol; 2021 Mar; 19(3):155-161. PubMed ID: 33739964 [TBL] [Abstract][Full Text] [Related]
22. ctDNA as an Adjunct to Posttreatment PET for Head and Neck Cancer Recurrence Risk Assessment. Lele SJ; Adilbay D; Lewis E; Pang J; Asarkar AA; Nathan CO Otolaryngol Head Neck Surg; 2024 Aug; 171(2):439-444. PubMed ID: 38591659 [TBL] [Abstract][Full Text] [Related]
23. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Cheng F; Su L; Qian C Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063 [TBL] [Abstract][Full Text] [Related]
24. Dynamics of cell-free tumour DNA correlate with treatment response of head and neck cancer patients receiving radiochemotherapy. Hilke FJ; Muyas F; Admard J; Kootz B; Nann D; Welz S; Rieß O; Zips D; Ossowski S; Schroeder C; Clasen K Radiother Oncol; 2020 Oct; 151():182-189. PubMed ID: 32687856 [TBL] [Abstract][Full Text] [Related]
25. Liquid biopsy in head and neck squamous cell carcinoma: circulating tumor cells, circulating tumor DNA, and exosomes. Yang WY; Feng LF; Meng X; Chen R; Xu WH; Hou J; Xu T; Zhang L Expert Rev Mol Diagn; 2020 Dec; 20(12):1213-1227. PubMed ID: 33232189 [No Abstract] [Full Text] [Related]
26. Liquid biopsy and their application progress in head and neck cancer: focus on biomarkers CTCs, cfDNA, ctDNA and EVs. Meng Y; Bian L; Zhang M; Bo F; Lu X; Li D Biomark Med; 2020 Oct; 14(14):1393-1404. PubMed ID: 33073579 [TBL] [Abstract][Full Text] [Related]
27. The diagnostic value and prospects of gene mutations in circulating tumor DNA for head and neck cancer monitoring. Yang X; Xu X; Zhang C; Ji T; Wan T; Liu W Oral Oncol; 2022 May; 128():105846. PubMed ID: 35358785 [TBL] [Abstract][Full Text] [Related]
29. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine. Van den Bossche V; Zaryouh H; Vara-Messler M; Vignau J; Machiels JP; Wouters A; Schmitz S; Corbet C Drug Resist Updat; 2022 Jan; 60():100806. PubMed ID: 35121337 [TBL] [Abstract][Full Text] [Related]
30. Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma. Payne K; Spruce R; Beggs A; Sharma N; Kong A; Martin T; Parmar S; Praveen P; Nankivell P; Mehanna H Head Neck; 2018 Jul; 40(7):1598-1604. PubMed ID: 29542214 [TBL] [Abstract][Full Text] [Related]
31. "Letter to the Editor: Next-Generation sequencing (NGS) profiling of matched tumor and Circulating Tumor DNA (ctDNA) in Head and Neck Squamous Cell Carcinoma (HNSCC)". Meivelu Moovendhan Oral Oncol; 2024 Oct; 157():106940. PubMed ID: 39013229 [No Abstract] [Full Text] [Related]
32. Development and validation of a targeted gene sequencing panel for application to disparate cancers. McCabe MJ; Gauthier MA; Chan CL; Thompson TJ; De Sousa SMC; Puttick C; Grady JP; Gayevskiy V; Tao J; Ying K; Cipponi A; Deng N; Swarbrick A; Thomas ML; Lord RV; Johns AL; Kohonen-Corish M; O'Toole SA; Clark J; Mueller SA; Gupta R; McCormack AI; Dinger ME; Cowley MJ; Sci Rep; 2019 Nov; 9(1):17052. PubMed ID: 31745186 [TBL] [Abstract][Full Text] [Related]
33. Circulating Tumor DNA in Human Papillomavirus-Mediated Oropharynx Cancer: Leveraging Early Data to Inform Future Directions. Heft Neal ME; Walline HM; Haring CT Cancer J; 2023 Jul-Aug 01; 29(4):215-219. PubMed ID: 37471611 [TBL] [Abstract][Full Text] [Related]
34. Head and Neck Squamous Cell Carcinoma Detection and Surveillance: Advances of Liquid Biomarkers. Swiecicki PL; Brennan JR; Mierzwa M; Spector ME; Brenner JC Laryngoscope; 2019 Aug; 129(8):1836-1843. PubMed ID: 30570748 [TBL] [Abstract][Full Text] [Related]
35. Upregulation of the long non-coding RNA CASC9 as a biomarker for squamous cell carcinoma. Sassenberg M; Droop J; Schulz WA; Dietrich D; Loick SM; Wiek C; Scheckenbach K; Gaisa NT; Hoffmann MJ BMC Cancer; 2019 Aug; 19(1):806. PubMed ID: 31412811 [TBL] [Abstract][Full Text] [Related]
36. Molecular and nutritional markers in head and neck cancer. Milano G; Gal J; Bensadoun RJ Curr Opin Oncol; 2024 May; 36(3):123-127. PubMed ID: 38441194 [TBL] [Abstract][Full Text] [Related]
37. A Study on the Correlations of the miR-31 Expression with the Pathogenesis and Prognosis of Head and Neck Squamous Cell Carcinoma. Qiang H; Zhan X; Wang W; Cheng Z; Ma S; Jiang C Cancer Biother Radiopharm; 2019 Apr; 34(3):189-195. PubMed ID: 30628842 [TBL] [Abstract][Full Text] [Related]
38. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer. van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217 [TBL] [Abstract][Full Text] [Related]
39. The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact. Mountzios G; Rampias T; Psyrri A Ann Oncol; 2014 Oct; 25(10):1889-1900. PubMed ID: 24718888 [TBL] [Abstract][Full Text] [Related]
40. Tracking the Molecular Fingerprint of Head and Neck Cancer for Recurrence Detection in Liquid Biopsies. Diez-Fraile A; De Ceulaer J; Derpoorter C; Spaas C; De Backer T; Lamoral P; Abeloos J; Lammens T Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269544 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]